8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Jan 8, 2026·SEC
Anika Therapeutics, Inc.(ANIK)Earnings, Financials & Key Ratios
ANIK•NASDAQ
$15.87
Price updated Jul 7, 2026
AboutAnika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.Show more
- Revenue$113M-5.9%
- EBITDA-$5M-276.2%
- Net Income-$11M+80.7%
- EPS (Diluted)-0.76+80.2%
- Gross Margin56.56%-10.8%
- EBITDA Margin-4.72%-287.3%
- Operating Margin-9.8%-130.3%
- Net Margin-9.64%+79.5%
- ROE-7.32%+76.2%
ANIK Price & Volume
Anika Therapeutics, Inc. (ANIK) stock price & volume — 10-year historical chart
Loading chart...
Strategic Pivot Strains Margins and Liquidity
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:Persistent negative operating margins
Key Thesis Takeaways
- Anika Therapeutics is currently navigating a challenging transition toward a direct sales model, which has resulted in significant revenue volatility and persistent operating losses.
- While the company maintains a conservative debt-to-equity ratio of 0.19, the erosion of retained earnings from $128.1M in 2023Q4 to $55.7M in 2026Q1 underscores the difficulty of achieving sustainable profitability.
- Investors should monitor whether the company can scale its direct sales force efficiently enough to offset the ongoing cash burn and negative operating margins of -18.5% observed in 2026Q1.
Verdict Logic
the company's inability to generate consistent positive free cash flow, evidenced by a $6.3M outflow in 2026Q1, combined with persistent negative operating margins, suggests significant execution risk during its commercial transition.
ANIK Growth Metrics
Anika Therapeutics, Inc. (ANIK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years1.95%
5 Years-2.86%
3 Years-0.3%
TTM23.22%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM80.5%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM79.62%
Return on Capital
10 Years4.53%
5 Years-1.31%
3 Years-2.83%
Last Year-6.35%
ANIK Recent Earnings
Anika Therapeutics, Inc. (ANIK) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
Apr 29, 2026Metric
Actual
Est
EPS
$0.27+485.7%
$0.07
Rev
$30M+5.2%
$28M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.31+348.0%
$0.13
Rev
$31M+6.0%
$29M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.04+100.0%
$0.02
Rev
$28M+0.1%
$28M
Q3 2025
Jul 30, 2025Metric
Actual
Est
EPS
$0.13+0.0%
$0.13
Rev
$28M+2.5%
$28M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $0.27vs $0.07+485.7% | $30Mvs $28M+5.2% |
| Q1 2026 | Feb 26, 2026 | $0.31vs $0.13+348.0% | $31Mvs $29M+6.0% |
| Q4 2025 | Nov 5, 2025 | $0.04vs $0.02+100.0% | $28Mvs $28M+0.1% |
| Q3 2025 | Jul 30, 2025 | $0.13vs $0.13+0.0% | $28Mvs $28M+2.5% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Anika Therapeutics, Inc. (ANIK)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $15.87 | $212.67M | -20.88 | -5.91% | -9.64% | -7.32% | — | |
| $4.20 | $623.98M | 13.13 | 19.99% | 7.88% | 12.86% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — | |
| $4.32 | $310.89M | -4.60 | -38.1% | -61.93% | -15.09% | — | |
| $32.80 | $1.66B | -136.67 | 14.88% | -0.83% | -0.95% | — | |
| $103.41 | $6.73B | 30.33 | 0.5% | 18.05% | 24.33% | — |
Compare ANIK vs Peers
Anika Therapeutics, Inc. (ANIK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ANIK SEC Filings & Documents
Anika Therapeutics, Inc. (ANIK) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ANIK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ANIK Frequently Asked Questions
Anika Therapeutics, Inc. (ANIK) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Anika Therapeutics, Inc.'s revenue?
Anika Therapeutics, Inc. (ANIK) reported $116.3M in revenue for fiscal year 2025. This represents a 9589% increase from $1.2M in 1996.
How fast is Anika Therapeutics, Inc. growing?
Anika Therapeutics, Inc. (ANIK) saw revenue decline by 5.9% over the past year.
Is ANIK profitable?
Anika Therapeutics, Inc. (ANIK) reported a net loss of $11.1M for fiscal year 2025.
Dividend & Returns
What is ANIK's return on equity?
Anika Therapeutics, Inc. (ANIK) has a return on equity (ROE) of -7.3%. Negative ROE indicates the company is unprofitable.
What is Anika Therapeutics, Inc.'s free cash flow?
Anika Therapeutics, Inc. (ANIK) generated $1.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.